Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.71 |
| ▸ | PTGIR | P43119 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8194068 | 0.84 | NISCH (0.77) | NISCHADRA2AADRA2BADRA2C | |
| SCHEMBL1288672 | 0.84 | NISCH (1.00) | NISCHPTGIRADRA2AADRA2BADRA2C | |
| SCHEMBL8201402 | 0.82 | NISCH (0.96) | NISCHPTGIRADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL8188726 | 0.80 | NISCH (0.50) | NISCHADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL9579892 | 0.80 | NISCH (0.81) | NISCH | |
| SCHEMBL8197935 | 0.80 | NISCH (0.75) | NISCH | |
| SCHEMBL8202723 | 0.80 | NISCH (0.75) | NISCH | |
| SCHEMBL8202988 | 0.79 | NISCH (0.71) | NISCHPTGIR | |
| SCHEMBL8196837 | 0.79 | NISCH (0.51) | NISCHADRA2AADRA2BADRA2CALDH1A1 | |
| SCHEMBL8231902 | 0.78 | NISCH (0.74) | NISCHPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000078726-A1 | IMIDAZOLINE DERIVATIVES FOR THE TREATMENT OF DIABETES, ESPECIALLY TYPE II DIABETES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |